Stancill JS, Corbett JA
Potential Benefits Works through amylin receptors rather than GLP-1, offering an alternative pathway for patients who may not respond optimally to GLP-1 medications alone
Patients who follow only some of those elements report variable results, which they then attribute to the device or the serum rather than to the protocol
The amyloidogenic core sequence of hIAPP (residues 2029, known as the FGAILS region) has been substituted to eliminate -sheet aggregation propensitya critical requirement for generating a stable, injectable research compound
[DOI] [PubMed] [Google Scholar] 41.Grabarevic Z., Tisljar M., Artukovic B., Bratulic M., Dzaja P., Seiwerth S., Sikiric P., Peric J., Geres D., Kos J